Dr. Brizuela conducted his graduate research at CSHL and postdoctoral work at Merck Sharp & Dohme Research Labs. He later took a scientist position at the EMBL and subsequently moved to Mitotix Inc. to work on cancer drug discovery. There he rose through the ranks of the organization, from senior scientist to head of the kinase inhibitor program and Director of Biochemistry across all drug discovery programs. He then moved to Harvard Medical School where he was Associate Director of the Harvard Institute of Proteomics as well as Director of the Proteomics Center for the Biodefense program at Harvard (NERCE) and faculty member of BCMP.
He joint Agilent Technologies, where he acted as Director of Science and Technology for the Genomics and Life Sciences groups and currently works under the CTO office as Associate Diretor of University Relations and External Research. Dr. Brizuela has produced influential work and numerous publications in the areas of cell cycle regulation, cancer biology, drug discovery and genomics. He is experienced with technology development/innovation. He has proven ability to build and execute scientific, technology development and product development activities, as well as to build collaborations and outsourcing within and across organizations.